Trials / Recruiting
RecruitingNCT06874335
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Confirmation Study of BHV-1530 in Adult Patients With Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 95 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-1530 | BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle |
Timeline
- Start date
- 2025-03-20
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
- First posted
- 2025-03-13
- Last updated
- 2025-11-18
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06874335. Inclusion in this directory is not an endorsement.